Cyber-deficiency-specific experience
- Blue Goat
- Letter review and scoped technical evidence updates
- Generic regulatory consultant
- Treats cyber as a regulatory writing task
- In-house
- First time under deadline pressure
Answer the FDA's cybersecurity questions with device-specific evidence. Fixed-fee quote after scoping.
Request a written scope instead275+ FDA submissions supported, zero cybersecurity rejections.
Last updated
Answer the FDA's actual cybersecurity questions with device-specific evidence. We review the letter, existing records, and patient-safety context before scoping document updates or testing. Your regulatory team reviews and submits the response. Fixed-fee quote within 24 hours of the scoping call.
FDA cybersecurity deficiency letter response services for medical device manufacturers.
Trusted by medical device teams worldwide
The proposal identifies included deliverables, exclusions, manufacturer inputs, and review responsibilities for this engagement.
Each cybersecurity question gets a numbered technical response with supporting evidence and page references. Cite the applicable law or guidance without assuming every concern is a Section 524B issue. The FDA decides whether the response addresses its concern.
Your regulatory team confirms the correspondence type, procedural status, and deadline. We agree technical work and dependencies against that actual letter.
Update the inventory or component assessment when the letter calls for it. SPDX is the default; CycloneDX can be agreed. VEX is optional communication of manufacturer-reviewed vulnerability assessments.
The letter and existing test records determine whether explanation, new testing, or retests are needed. Agree interfaces, build versions, access, exclusions, and engineering dependencies before testing.
Each item follows the same order: concern, response, evidence, and location in the submission.
One quote covers the response and any follow-up exchanges until the cybersecurity file is closed. No retest invoices.
Review these evidence areas against the actual letter. The letter, existing records, and testing needs determine the response scope.
Review the inventory and component assessments against the actual concern. SPDX is our default format. VEX is optional; its absence alone does not establish a deficiency. Updates are scoped to the evidence needed.
Check system coverage, data flow diagrams, trust boundaries, and threat-to-control traceability. We scope the threat model and Threat Table updates needed. Security architecture views are separate deliverables.
Identify the missing test evidence, affected interfaces, and device build. New testing or retests depend on the concern and existing coverage; neither a full rebuild nor a targeted retest is assumed.
Missing traceability between Section 524B(b)(1)-(3) requirements and submission artifacts. We deliver a refreshed matrix that points each requirement to its evidence.
Check whether secure development records describe the manufacturer's actual processes and evidence. Documentation updates and QMS implementation work are scoped separately; your quality team approves its processes.
Reviewer wants a credible coordinated vulnerability disclosure (CVD) process, SBOM monitoring plan, and patch cadence. We document what you'll actually do.
Discuss architecture, available records, access, responsibilities, and target dates. Agree confidential handling before transferring device material.
The proposal identifies included work, exclusions, manufacturer inputs, and delivery milestones. The 24-hour quote turnaround is separate from delivery, remediation, and review time.
Update the artifacts and testing identified by the letter review. Deliver a point-by-point response with evidence references for your regulatory team to review and submit. The FDA decides the outcome.
"Their report helped us achieve FDA clearance without any additional questions. It was a truly seamless experience."
"Blue Goat's niche expertise in FDA-facing cybersecurity made all the difference. Their reports were built with the FDA's expectations in mind; it gave us confidence that we were submitting exactly what reviewers want to see."
"The organized documentation, perfectly formatted for eSTAR, saves us countless hours. Their expertise and smooth process mean we can focus on our product, not the paperwork."
What you actually get versus a generic regulatory consultant or re-spinning the cybersecurity attachment in-house against the 180-day clock.
| Capability | Blue Goat Cyber | Generic regulatory consultant | In-house |
|---|---|---|---|
| Cyber-deficiency-specific experience | Letter review and scoped technical evidence updates | Treats cyber as a regulatory writing task | First time under deadline pressure |
| Response dates based on the actual letter | Dates agreed after letter and evidence review | Hourly, drifts with scope | Competes with engineering work |
| Maps response point-by-point to the letter | Mirrors reviewer's exact ordering | General rewrite, gaps remain | Built from scratch, easy to miss items |
| eSTAR-attachable cover letter + evidence | Evidence mapped for manufacturer review and assembly | Word docs that need reformatting | Reformatted each time |
| Pricing model | Fixed fee, revisions included | Hourly + change orders | Hidden internal cost |
If the FDA raises a cybersecurity question, we answer it at no extra cost until the cybersecurity portion is closed.
We sign a mutual NDA before the initial call so you can share device details, architecture, and FDA correspondence freely.
The quote identifies deliverables, assumptions, and dates. Quote turnaround is separate from the time needed to deliver the work.
Senior-led cybersecurity work within the agreed scope. Your team reviews the evidence and owns risk, release, and submission decisions.
Yes. We complete a mutual NDA before the initial 30-minute call. You can share the FDA letter, device architecture, and submission artifacts freely once it's in place.
Yes. Confirm the correspondence type, procedural status, and deadline with your regulatory team. Additional Information (AI) does not mean artificial intelligence. We map the actual cybersecurity questions to explanations, document updates, analysis, or testing. Not every letter requires the same work.
We deliver the cybersecurity response package in 30 days or less from kickoff, once we have the FDA letter, existing documentation, and test access. Engineering fixes on your side, retests, and your regulatory review can add time, so we agree dates against your actual FDA deadline before work starts.
The free 30-minute call, under mutual NDA. A senior specialist reads the actual letter with you, flags which concerns need new evidence versus rewording, and you get a written scope and fixed-fee quote within 24 hours. You decide after that; there is no commitment on the call.
The proposal lists the point-by-point technical response, evidence references, and any document updates or testing needed. SPDF, SBOM, threat model, Threat Table, architecture views, and testing work are included only when identified in that scope. VEX is optional. Engineering fixes, risk acceptance, and submission stay with the manufacturer.
If the FDA raises a cybersecurity question, we answer it at no extra cost until the cybersecurity portion is closed. Your regulatory team reviews and submits the response. The FDA makes the regulatory decision.
Yes. We can scope technical review and response support or preparation of the agreed documents. Your regulatory team retains review and submission responsibility.
Who you're talking to
MBA, CISSP · U.S. Air Force Academy graduate · 30+ years in cybersecurity
Christian leads the senior medical device cybersecurity team behind 275+ FDA submissions supported, zero cybersecurity rejections. Author of three books including Medical Device Cybersecurity: An In-Depth Guide.
30-minute call with a senior medical device cybersecurity expert. Mutual NDA signed before the call. Fixed-fee quote within 24 hours of the scoping call. Response delivery dates are agreed separately.